Outlook Therapeutics, Inc. current report, 15 March 2019

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Outlook Therapeutics, Inc. on March 15, 2019. The company is incorporated in Delaware and operates as an emerging growth company. The report details a material corporate action regarding the company's capital structure.

Key Financial Metrics

The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed relates to the company's share count:

  • Pre-Split Shares Outstanding: Approximately 94.1 million shares.
  • Post-Split Shares Outstanding: Approximately 11.8 million shares.
  • Par Value: $0.01 per share (unchanged).

Material Changes

The company effected a one-for-eight reverse stock split of its issued and outstanding common stock immediately upon filing a Certificate of Amendment with the Delaware Secretary of State. Key changes include:

  • Every eight shares of common stock were combined into one share.
  • Stockholders entitled to fractional shares received a proportional cash payment instead of fractional stock.
  • Outstanding options, warrants, and convertible securities were adjusted in accordance with their terms.
  • The authorized number of shares of common stock remained unchanged.

Guidance, Outlook, and Management Commentary

Trading of the common stock on a reverse stock split-adjusted basis commenced on the Nasdaq Capital Market on March 18, 2019. The stock began trading under a new CUSIP number (69012T206). The reverse stock split was authorized by stockholders at the 2018 Annual Meeting, which granted the Board discretion to execute a split ratio between one-for-two and one-for-ten. American Stock Transfer & Trust Company, LLC is acting as the exchange agent.

Investor Verification Checklist

  • Verify the adjusted share count and new CUSIP number (69012T206) in brokerage accounts.
  • Confirm receipt of cash payments for any fractional shares if applicable.
  • Review the adjustment terms for any held options, warrants, or convertible securities.
  • Check the full text of the Certificate of Amendment (Exhibit 3.1) for complete legal details.